How-To Guide
How to Use AI for a Urology Practice in 2026: BPH, Stones, Prostate Cancer & Cystoscopy Workflows
Published May 19, 2026 · 16 min read · For urologist-owners of 1-5 MD urology practices — general, stone disease, BPH, prostate cancer, oncology, pediatric, female pelvic medicine, and men's health.
TL;DR for urologist-owners
The 2026 urology AI stack that actually ships revenue is (1) an ambient scribe that pauses for cysto and genital exam, (2) structured intake that auto-scores AUA-SI/IPSS, OAB-q, SHIM/IIEF-5, and EPIC-26, (3) a stone-disease protocol that pulls CT KUB metrics and prior metabolic workup, (4) a PSA/mpMRI/PI-RADS pipeline that drafts the shared-decision note for MRI-fusion biopsy, (5) a prior-auth drafter tied to payer medical policy and AUA guidelines, and (6) an owner scorecard that reads from the EHR and AUA Quality Registry (AQUA). Everything else is noise. The urologist still owns the decision; AI owns the typing.
The 2026 urology AI stack (what actually earns its keep)
A 1-5 urologist practice running a typical mix of office visits, in-office procedures (cystoscopy, prostate biopsy, UroLift, Rezum, Optilume, BTL urethral dilation), and OR time (TURP/HoLEP/Aquablation, stone surgery, robotic prostatectomy/nephrectomy/cystectomy, sling/mesh revision) has four high-leverage AI surfaces: documentation, triage/intake, imaging decision-support, and prior auth. The rest is vendor theater. Here is the concrete stack I recommend ownership actually pay for:
| Surface | Representative tools | What it earns |
|---|---|---|
| Ambient scribe (urology-capable) | Heidi, Abridge, DeepScribe, Suki Assistant, Nuance DAX Copilot, Freed, Sunoh.ai | 6-10 hr/wk/clinician back |
| Urology EHR + PM | Modernizing Medicine EMA Urology, UroChart by Intuitive, Meditab IMS Urology, NextGen Urology, athenaOne, eCW, Epic Urology, Oracle Cerner Millennium | Template-native coding, AQUA export |
| Prostate MRI + PI-RADS AI | Quantib Prostate, Avenda Health iQuest, Siemens AI-Rad Companion Prostate MR, Philips DynaCAD Prostate, Bot Image ProstatID | Cleaner biopsy decisions, fewer re-reads |
| MRI-fusion biopsy | Artemis (Eigen), UroNav (Philips/Invivo), Koelis Trinity, MIM Symphony, BK 3500 Fusion | Higher csPCa detection |
| Risk + screening tools | Stockholm3 (A3P Biomedical), 4Kscore, PHI, SelectMDx, ExoDx, MyProstateScore 2.0 (MPS2), Confirm MDx, Decipher Prostate, Prolaris, Oncotype Dx GPS | Defensible "biopsy or not" calls |
| Stone workup + Rx | Litholink (LabCorp) 24-hr urine, Dornier Delta III, Storz Modulith, EDAP Sonolith, Olympus scopes, Boston Scientific LithoVue, Quanta System Cyber TM, Lumenis MOSES 2.0 | AUA-guideline stone plans |
| BPH therapy stack | Rezum (Boston Scientific), UroLift (Teleflex), iTind (Olympus), Aquablation (PROCEPT BioRobotics AquaBeam), Optilume BPH (Laborie), HoLEP (Lumenis MOSES 2.0), PVP GreenLight XPS, Urolift 2, robotic simple prostatectomy | Right procedure, right patient, right code |
| OAB / incontinence / neuromodulation | Medtronic InterStim X + Micro, Axonics R20 + F15, Uro-1 PTNS, Urgent PC, Botox 100U intradetrusor, Gemtesa, Myrbetriq, Toviaz, Vesicare LS | Stepwise 3rd-line OAB plans |
| Prior auth + denials | CoverMyMeds, Glidian, Myndshft, Rhyme, Olive AI, Experity, Waystar, Availity | PA letter first-pass in minutes |
| Reviews + recall | Weave AI, NexHealth, Doctible, RevenueWell, Solutionreach, Klara, Phreesia AI, BirdEye, Podium, NiceJob | PSA/stone/CBC-UA recall on autopilot |
| Quality + MIPS | AUA Quality (AQUA) Registry, MIPS MVP for Urology (where CMS finalizes), Medisolv, Healthmonix, MDinteractive | CMS MIPS upside; avoid the 9% cut |
A few things explicitly not on this list: AI that claims to "diagnose prostate cancer from a PSA alone," AI that writes operative reports you did not dictate, AI chatbots that advise patients on erectile dysfunction or fertility without a clinician in the loop, and any tool that does not produce a BAA. If a vendor will not sign a BAA in 2026, they are not a healthcare vendor.
10 prompts a urology practice should keep in 2026
Drop these into your ambient-scribe, EHR smart-phrase library, or a private LLM workspace. Every one of them ends with "do not make up content — ask me if uncertain." That single line is the difference between a useful draft and a liability.
1. New-patient intake synthesis
You are a urology intake summarizer. Input: the patient's intake form, uploaded records, med list, imaging reports, prior labs (PSA series, UA, cultures, BMP, testosterone), and prior operative notes. Output, in <= 250 words for the urologist's pre-visit read:
1) Chief complaint(s) in the patient's own words, grouped (LUTS/BPH, hematuria, stones, UTI, ED/male infertility, incontinence/OAB, scrotal/testicular, oncologic follow-up).
2) Timeline of prior urologic care: prior cystos, biopsies (date + cores + Gleason + ISUP), stone events + composition, prior surgeries.
3) Current meds relevant to urology (alpha blockers, 5-ARI, beta-3 agonists, antimuscarinics, PDE5, testosterone, anticoagulants, diuretics, GLP-1s).
4) Red flags to raise at minute 0: gross hematuria, recurrent febrile UTI, rising PSA trajectory, testicular mass, acute scrotum, obstructive uropathy signs, suspected cauda equina with urinary retention.
5) Questionnaires auto-scored: AUA-SI/IPSS, OAB-q, SHIM/IIEF-5, EPIC-26, NIH-CPSI, ICIQ-SF — report score + interpretation band.
6) Coverage + prior auth flags (Medicare, MA, Medicaid, commercial) for likely orders.
Do not diagnose. Do not recommend therapy. Flag anything missing (last PSA date, last UA, imaging) and ask me before finalizing. Do not make up content.
2. Ambient-scribed urology SOAP
You are a HIPAA-safe ambient scribe for a urology visit. Input: the recorded encounter (with patient consent captured in intake), the intake summary, prior notes, and latest labs/imaging.
Produce a SOAP note with:
- S: HPI in the urologist's voice, ROS (GU-focused + cardiopulmonary + musculoskeletal as relevant), PMH/PSH/FHx/SHx, meds, allergies.
- O: vitals, focused GU exam (pause-and-resume — do not transcribe the physical exam itself; resume at post-exam discussion), in-office testing (UA dipstick, post-void residual, uroflow, PSA if resulted), in-office procedure note if performed (cystoscopy 52000, bladder biopsy 52204, urethral dilation 52281, prostate biopsy 55700/55706, UroLift 52441/52442, Rezum 53854, bladder Botox 52287).
- A: numbered problem list with ICD-10.
- P: numbered plan — meds with dose/route/frequency/duration, labs/imaging ordered, procedures scheduled, referrals, patient education (include teach-back), follow-up interval.
Append: CPT/E&M suggestion (99202-99205 new, 99212-99215 established) with MDM level rationale + any add-on code (+99417 prolonged, 96127 questionnaire, 51798 PVR, 51741 uroflow, 52000 cysto, G0508/G0509 for complex MDM where relevant). Flag any missing elements that would down-code. Do not make up content.
3. BPH workup + shared-decision note (AUA/SUFU 2023)
You are a BPH shared-decision drafter. Input: patient age, prostate size (DRE estimate + TRUS/MRI if available), AUA-SI/IPSS + bother, median lobe presence, post-void residual, uroflow Qmax, prior meds tried + response + side effects, sexual function (erectile + ejaculatory), anticoagulation status, comorbidities (anesthesia risk), patient priorities (sexual preservation, one-and-done, avoiding catheter, fastest recovery).
Produce a structured shared-decision note:
1) Severity band: mild (IPSS 0-7), moderate (8-19), severe (20-35), with bother score.
2) Guideline-aligned option matrix (medical: alpha blocker, 5-ARI, combo, beta-3 add-on, PDE5 daily; MIST: Rezum, UroLift, iTind, Optilume BPH; surgical: Aquablation, HoLEP, TURP, PVP, robotic simple prostatectomy) — include anatomic qualifiers (size, median lobe, prior retention, anticoagulation).
3) What the evidence says for THIS patient's profile — not generic talking points.
4) Retrograde-ejaculation / ED / urge-incontinence risk table by option.
5) Recovery + catheter expectations by option.
6) My recommendation placeholder: "Urologist to confirm based on exam and patient priorities."
Do not recommend. Do not make up anatomic findings. Ask me if prostate size, median lobe, or anticoagulation status is missing. Do not make up content.
4. Stone-disease protocol (AUA 2016 + 2019 amendments)
You are a urinary-stone protocol drafter. Input: CT KUB report (stone location, size in mm, Hounsfield units, hydronephrosis grade, skin-to-stone distance), UA + culture, BMP, stone-event history, prior stone composition if known, metabolic workup history (Litholink 24-hr urine x2 baseline), current meds, comorbidities (diabetes, obesity, gout, IBD, bariatric surgery, primary hyperparathyroidism).
Produce:
1) Acute-management recommendation per AUA Surgical Management of Stones: observation with MET (tamsulosin) vs. SWL vs. URS + laser (MOSES 2.0 / holmium) vs. PCNL vs. stent + delayed intervention — based on size, location, HU, and patient factors.
2) Infection-stone / sepsis red flags — obstructing + febrile + leukocytosis = decompress TODAY.
3) Metabolic-workup plan per AUA Medical Management of Stones: two 24-hr urines (Litholink), stone composition (send to Beck Analytical / Mayo / Louis Herring), serum PTH if calcium elevated, uric acid if uric-acid stone suspected.
4) Dietary + pharm plan by stone type (calcium-oxalate, calcium-phosphate, uric-acid, cystine, struvite) — fluid goal >2.5 L/day, sodium <2300 mg, normal calcium 1000-1200 mg, moderate animal protein, oxalate awareness; thiazide for hypercalciuria; potassium citrate for hypocitraturia or uric-acid stones; allopurinol for hyperuricosuria; tiopronin for cystine.
5) Follow-up cadence (imaging + labs) — 3 mo post-intervention, then 6-12 mo.
Do not recommend a specific procedure without confirming patient anticoagulation, anesthesia risk, and anatomic suitability. Do not make up content.
5. PSA / prostate-cancer workup + MRI-fusion biopsy plan
You are a prostate-cancer workup drafter aligned to AUA/SUO Early Detection of Prostate Cancer 2023 and NCCN Prostate Cancer Early Detection.
Input: age, race, family history (BRCA1/2, Lynch, first-degree PCa), PSA trajectory (last 3-5 values + velocity + density), free-to-total PSA, DRE findings, prior biopsy history (dates + cores + Gleason/ISUP + percent involvement), reflex marker results (4Kscore, PHI, SelectMDx, ExoDx, MPS2, Stockholm3, Confirm MDx), mpMRI report (PI-RADS v2.1 per lesion + PSAD + extracapsular extension + seminal-vesicle invasion + lymph nodes).
Produce:
1) Risk stratification narrative (low / intermediate-favorable / intermediate-unfavorable / high / very-high) with the specific inputs driving it.
2) Next-step recommendation: repeat PSA / reflex marker / mpMRI / MRI-fusion biopsy (systematic + targeted) / active surveillance / treatment discussion — guideline-cited.
3) Biopsy plan if indicated: platform (Artemis / UroNav / Koelis / MIM Symphony), anesthesia (local vs. MAC), route (transperineal preferred per AUA 2023 for infection reduction vs. transrectal with prophylaxis), number of targeted cores per lesion + systematic template, anticoagulation hold plan.
4) Shared-decision touchpoints — overtreatment risk, biopsy complications, active surveillance eligibility.
5) Genomic-classifier trigger (Decipher Prostate / Prolaris / Oncotype Dx GPS) for intermediate-risk treatment decisions.
Do not state a treatment plan without urologist sign-off. Do not make up PI-RADS scores or PSA values. Do not make up content.
6. Cystoscopy + hematuria workup (AUA 2020 Microhematuria)
You are a hematuria workup drafter per AUA Microhematuria 2020 guideline.
Input: gross vs. microscopic hematuria, degree (RBC/HPF), timing (initial/terminal/total), associated symptoms (LUTS, flank pain, clots, dysuria, constitutional), risk factors (age, sex, smoking pack-years, occupational exposures — aromatic amines, aniline dyes, benzene, hairdresser/painter/leather/rubber, pelvic radiation, cyclophosphamide, Lynch syndrome, indwelling catheter), prior hematuria workup, concurrent UTI, anticoagulation.
Produce:
1) Risk stratification per AUA 2020 — low (< age 40, never smoker, 3-10 RBC/HPF), intermediate, high. Use specific inputs.
2) Workup recommendation: low-risk = shared decision (repeat UA in 6 mo OR cysto + renal US); intermediate = cysto + renal US; high = cysto + CT urogram. State the rationale.
3) Cystoscopy setup: flexible vs. rigid, sedation plan, CPT (52000 dx, 52204 biopsy, 52224 fulguration, 52234/52235/52240 TURBT), consent language (bleeding, infection, false passage, retention, need for biopsy/fulguration).
4) If mass found: TURBT plan + BCG/gemcitabine/docetaxel or MMC induction per AUA/SUO NMIBC; if muscle-invasive suspected, cystectomy + diversion discussion + medical oncology referral.
5) Follow-up: UroVysion / Cxbladder / BTA / CellDetect — when useful, not reflex.
Do not assign risk without confirming age, smoking history, and RBC/HPF. Do not make up findings. Do not make up content.
7. OAB / urinary incontinence stepwise plan (AUA/SUFU OAB 2024)
You are an OAB / incontinence plan drafter.
Input: OAB-q + ICIQ-SF + 3-day voiding diary, urge vs. stress vs. mixed incontinence, PVR, uroflow, urodynamics if done, prior pelvic-floor PT, prior behavioral therapy, prior first-line meds (antimuscarinics — oxybutynin, tolterodine, solifenacin, darifenacin, trospium) and beta-3 agonists (mirabegron/Myrbetriq, vibegron/Gemtesa), side effects, comorbidities (dementia, glaucoma, constipation), pregnancy/lactation status.
Produce:
1) Line-of-therapy framing: 1st = behavioral + pelvic-floor PT, 2nd = pharm (antimuscarinic or beta-3 — prefer beta-3 in elderly/dementia/anticholinergic-burden), 3rd = advanced therapy (PTNS — Uro-1, Urgent PC; intradetrusor Botox 100U; sacral neuromodulation InterStim X / Axonics R20).
2) Recommendation with guideline-cited rationale for THIS patient.
3) Stress-incontinence path: PFPT + pessary + urethral bulking (Bulkamid) + sling (retropubic, transobturator, single-incision) + state-specific mesh informed consent.
4) Urodynamics indication — not reflex; only if dx unclear, prior surgery, neurogenic, or pre-advanced therapy.
5) Prior-auth preview for Botox/SNM/PTNS with payer medical policy cites and required failed-therapy trail.
Do not recommend advanced therapy without 12-week 2nd-line trial documented. Do not make up content.
8. Male infertility + ED workup (AUA/ASRM 2024)
You are a men's-health workup drafter aligned to AUA/ASRM Male Infertility 2024 and AUA ED 2018 (amended).
Input: chief complaint (infertility vs. ED vs. low T vs. Peyronie's vs. post-vasectomy regret vs. varicocele), duration, SHIM/IIEF-5, semen analyses (x2 per WHO 6th ed. — volume, concentration, motility, morphology, DFI if indicated), AM testosterone x2 + LH + FSH + prolactin + estradiol + SHBG + free T calc, physical exam findings (varicocele grade I/II/III, testicular volume via orchidometer, vas deferens present, Peyronie plaque + curvature + deformity), cardiovascular risk profile, prior paternity, current meds (testosterone, finasteride, SSRIs, opioids, anabolic steroids).
Produce:
1) Diagnostic framing: hypergonadotropic vs. hypogonadotropic vs. primary testicular vs. obstructive azoospermia vs. functional ED vs. organic ED vs. Peyronie's.
2) Next-test recommendation (scrotal US, karyotype + Y-microdeletion for severe oligo/azoospermia, CFTR for CBAVD, TRUS for ejaculatory-duct obstruction, pituitary MRI for hypogonadotropic, penile Doppler for vasculogenic ED, dynamic infusion cavernosometry only if indicated).
3) Therapy matrix: lifestyle, clomiphene/enclomiphene for secondary hypogonadism preserving fertility, hCG + FSH for hypogonadotropic infertility, varicocelectomy criteria, microTESE for NOA, vasovasostomy vs. vasoepididymostomy, PDE5 (sildenafil/tadalafil/avanafil), ICI (Trimix, alprostadil), VED, penile prosthesis (AMS 700, Coloplast Titan), Xiaflex for Peyronie's with specific curvature/plaque criteria.
4) When to refer to REI + mental health.
Do not prescribe testosterone for fertility. Do not confirm hypogonadism without two AM values. Do not make up content.
9. Prior-auth + denial-appeal drafter
You are a urology prior-auth drafter.
Input: patient EHR, payer + plan + member ID, procedure/drug/device being requested (Rezum, UroLift, Aquablation, HoLEP, Botox intradetrusor, InterStim/Axonics, Xiaflex, Bulkamid, inflatable penile prosthesis, Optilume, iTind, enclomiphene, GLP-1 for stone risk), CPT/HCPCS + diagnosis codes, payer medical-policy number, and the patient's failed-conservative-therapy trail with dates + drug + dose + duration + reason for discontinuation.
Produce a PA letter with:
1) Header: patient demographics, insurance info, rendering + ordering provider NPIs + TIN, date of service, place of service.
2) Clinical narrative: symptom severity with scored questionnaires (AUA-SI/IPSS, OAB-q, SHIM), objective findings (PVR, uroflow, prostate size, urodynamics), imaging, prior interventions.
3) Failed-conservative-therapy table mapped exactly to the payer's medical-policy requirements — do not skip any required row.
4) Guideline citations: AUA + SUFU + NCCN + payer policy number.
5) Medical-necessity statement tying THIS patient to policy criteria.
6) Closing + signature block for the urologist.
If denied: appeal letter with peer-reviewed citations, guideline quotes, state external-review information, and request for peer-to-peer within the plan's timeframe. Do not make up evidence or guidelines. If a required failed-therapy row is missing, STOP and ask me. Do not make up content.
10. Urologist-owner monthly scorecard
You are a urology-practice owner dashboard. Input: EHR + PM + AQUA Registry exports for the past 30/90/365 days. Output, <= 500 words, plain English for the owner's Monday coffee:
1) Volume + mix: new vs. established ratio, encounter count by subspecialty (BPH, stones, prostate-cancer, OAB, men's health, oncology surveillance), in-office procedures (cysto 52000, biopsy 55700/55706, UroLift, Rezum, Aquablation referral, Botox 52287), OR volume (TURP/HoLEP/Aquablation, robotic — RALP, partial neph, cystectomy, sling).
2) Revenue per clinician-hour + per procedure-hour, with trend.
3) AR aging buckets (0-30/31-60/61-90/>90), denial rate by payer + top 3 denial reasons.
4) AUA AQUA Registry flags: BPH-IPSS documentation, prostate-cancer active-surveillance adherence, UTI-recurrent appropriate workup, hematuria guideline-concordance, stone MET + 24-hr urine ordering rate.
5) MIPS: Quality + Promoting Interoperability + Improvement Activities + Cost — estimated final score + $ at risk.
6) No-show + same-day-cancel by subspecialty; recall-queue depth (PSA, post-stone imaging, post-BCG, post-TURBT surveillance).
7) Staff ratio: clinician-hours covered per MA/RN/APP-hour.
8) Two specific actions for next week that would each move one KPI by at least 10% — with the EHR/PM report the owner should pull to verify.
Do not invent numbers. If a data source is missing, say so and stop. Do not make up content.
Compliance floor (the non-negotiables for 2026)
- HIPAA + BAA: 45 CFR 160 & 164. Every AI vendor that touches PHI signs a BAA. Minimum-necessary defaults. §164.514 de-identification standards for any analytics export. §164.502(a)(5)(iii) 2024 Reproductive Health amendments apply when contraception or male/female sterilization content is involved.
- State AI-scribe / AI-use consent: California AB 3030 (eff Jan 1 2025) — generative-AI notice in patient communication. Texas SB 815 (eff Sep 1 2025). Utah HB 452 AI Mental Health Policy Act. Illinois HB 1806 (eff Jan 1 2026). New York S1331A pending. Put the notice in intake + signage + portal; do not rely on mid-visit verbal consent.
- FDA 510(k) AI-SaMD: Every imaging AI you cite in a note (Quantib, Avenda iQuest, Siemens AI-Rad Companion, Philips DynaCAD, Bot Image) has a clearance. Know the indication and intended use. AI is second-reader, not primary read. The FDA Predetermined Change Control Plan (PCCP) framework governs model updates.
- AUA clinical practice guidelines: BPH (2023), Early Detection of Prostate Cancer (2023), Surgical + Medical Management of Stones (2016/2019 amendments), Microhematuria (2020), OAB (2024), Male Infertility (2024), Muscle-Invasive Bladder (2020), NMIBC (2024 amendment), ED (2018 amended), Peyronie's, Vasectomy, Urodynamics, Testosterone Deficiency, Female SUI, Recurrent UTI. Cite by name + year when the AI drafts clinical rationale.
- CMS MIPS + quality: MIPS final rule 2026 + MVP Advancing Cancer Care / Surgical Care where CMS finalizes for urology. AQUA Registry (AUA) as the qualified clinical data registry. Measures: BPH IPSS documentation, prostate-cancer active-surveillance, UTI workup, hematuria workup, catheter-associated UTI prevention.
- DEA + controlled-substance: EPCS under SUPPORT Act + 21 CFR 1306 + state PDMP queries before every C-II (CA CURES, TX PMP, FL E-FORCSE, NY I-STOP, OH OARRS). MATE Act 8-hour training (DEA renewal since June 2023). Relevant to urology for post-op analgesia, Xiaflex pain management, post-stone opioid prescribing (CDC 2022 guideline: 7-day limit, lowest effective dose, co-prescribe naloxone when indicated).
- AKS / Stark: Device-rep relationships with Boston Scientific (Rezum), Teleflex (UroLift), PROCEPT (Aquablation), Olympus (iTind, scopes), Medtronic (InterStim), Axonics, Laborie (Optilume) — FMV consulting agreements, no per-case steering, Open Payments Sunshine Act reporting, physician-owned distributorship OIG advisory awareness.
- FTC + advertising: FTC Endorsement Guides (2023) + Fake Reviews Rule 16 CFR 465 + $51,744/violation FY 2026 + FTC Act §5 UDAP + state medical-board advertising rules. No incentivized reviews. Typical-results disclosures on before/after for Peyronie's, penile prosthesis, or any cosmetic claim.
60-day rollout for a 1-5 urologist practice
- Week 1-2: Sign BAAs with ambient-scribe vendor + review-and-recall vendor. Update intake form + signage + portal with state AI-use notice. Pilot one urologist + one APP for two weeks.
- Week 3-4: Go live for all clinicians with ambient scribe. Build EHR smart phrases from the 10 prompts. Turn on PDMP integration in EHR if not already. Route prior-auth letters through CoverMyMeds/Glidian for Rezum, UroLift, Aquablation, Botox, InterStim.
- Week 5-6: Connect AUA AQUA Registry export. Review first two weeks of scribed notes for down-coding risk — MDM level, add-on codes (+99417, 96127, 51798, 51741). Spot-check 10% of prostate-MRI PI-RADS summaries against the radiologist's read.
- Week 7-8: Launch monthly owner scorecard. Replace one manual weekly task per clinician with an AI-drafted workflow (recall queue, prior-auth letter, or denial appeal). Review state AI-use compliance + update staff training log.
Common mistakes urology practices make with AI in 2026
- Using a general-purpose ambient scribe without a urology template — misses AUA-SI/IPSS, PVR, uroflow, cysto procedure codes, and MDM-level add-ons.
- Letting the scribe record the physical exam and cystoscopy itself. Pause-and-resume is non-negotiable; the procedure note is separate.
- Signing AI-drafted prior-auth letters without verifying the failed-therapy trail. Payers deny on a single missing row.
- Trusting an AI PI-RADS tool as a primary read. Radiologist reads; AI assists.
- Skipping state AI-use consent because "HIPAA covers it" — it does not cover California AB 3030, Texas SB 815, Utah HB 452, or Illinois HB 1806.
- Auto-prescribing testosterone in a man pursuing fertility. AI should flag and stop.
- Running patient-facing AI chat for ED/fertility/LUTS without a clinician-in-the-loop sign-off — that is practicing medicine.
- Marketing "AI-powered prostate-cancer detection" — FTC §5 UDAP + state medical-board advertising + FDA labeling all apply.
FAQ
Is an AI ambient scribe safe for a urology visit that includes a genital exam or cystoscopy?
Yes, with the usual guardrails plus a urology-specific discipline around sensitive content. Require a signed BAA, explicit patient consent (folded into intake, not a mid-visit pop-up), and a workflow that pauses recording during the physical exam and cystoscopy itself — the scribe captures the pre-procedure discussion, indication, consent, and post-procedure plan, not the live procedure. California AB 3030 (eff Jan 2025), Texas SB 815, Utah HB 452, and Illinois HB 1806 require generative-AI notice in clinical communication. Most urology-friendly tools (Heidi, Abridge, DeepScribe, Suki, Nuance DAX Copilot, Freed, Sunoh.ai) have a pause-and-resume flow.
Can AI read a prostate mpMRI or interpret a PI-RADS score?
AI-assisted PI-RADS tools (Quantib Prostate, Avenda Health iQuest, Siemens AI-Rad Companion Prostate MR, Philips DynaCAD Prostate, Bot Image ProstatID) are FDA-cleared as decision-support — they assist lesion detection and volumetry and feed a structured PI-RADS v2.1 report. The radiologist reads the study; the urologist interprets it for the patient. AI is a second-reader aid, not a primary read. For MRI-fusion biopsy (Artemis, UroNav, Koelis Trinity, MIM Symphony), AI handles the contour registration; the urologist still plans and places the cores.
How does AI help with BPH workup and shared decision-making?
The AUA/SUFU BPH guideline (2023 amendment) expects documented AUA Symptom Index (AUA-SI) / IPSS, bother score, and a structured discussion of medical therapy (alpha blocker, 5-ARI, combination, beta-3 agonist add-on) versus minimally invasive surgical therapy (Rezum, UroLift, iTind, Optilume BPH, Aquablation, HoLEP, PVP, robotic simple prostatectomy). AI can auto-score the IPSS from intake, summarize meds tried and response, and draft the shared-decision note with the options the patient qualifies for — but the recommendation is the urologist's.
Can AI handle prior auth for urology drugs and procedures?
Yes, for the letter and evidence assembly — not the medical judgment. GLP-1 for stones, Botox for OAB, sacral neuromodulation (Medtronic InterStim, Axonics), Rezum, UroLift, Aquablation, HoLEP, iTind, Optilume, and several oncology agents still need prior auth on most plans. AI pulls the failed-conservative-therapy trail, matches it to the payer's medical policy and AUA guideline, and drafts a letter the urologist signs. CMS MAC LCDs and InterQual/MCG criteria are the authoritative source; AI is a drafting layer.
Does AI pay off in a 1-3 urologist practice?
Yes, and the return is concentrated on documentation and prior auth. A solo urologist doing 25-35 encounters/day plus cysto and in-office procedures typically spends 8-12 hours/week on after-hours charting. An ambient scribe plus templated in-office procedure notes recaptures 60-80% of that. For a urologist billing 99214/99215 plus 52000/51798/52332/52283, the recaptured time converts to 8-12 additional appointments/week or a real life outside clinic. The ambient stack runs $150-350/month per clinician; the rest of the workflow tooling is usually inside the EHR.
Sources & further reading
- AUA Clinical Practice Guidelines — BPH (2023), Early Detection of Prostate Cancer (2023), Stones (2016/2019), Microhematuria (2020), OAB (2024), Male Infertility (2024), NMIBC (2024), ED (2018 amended).
- HHS OCR — HIPAA 45 CFR 160 & 164, BAA requirements, §164.514 de-identification.
- CA AB 3030 (eff Jan 2025); TX SB 815 (eff Sep 2025); UT HB 452; IL HB 1806 (eff Jan 2026); NY S1331A pending.
- FDA — 510(k) clearances for Quantib Prostate, Avenda Health iQuest, Siemens AI-Rad Companion Prostate MR, Philips DynaCAD Prostate, Bot Image ProstatID. FDA PCCP framework.
- CMS MIPS Final Rule 2026; AUA Quality (AQUA) Registry; DEA EPCS + 21 CFR 1306; MATE Act 2023.
- FTC Endorsement Guides (2023); Fake Reviews Rule 16 CFR 465; FTC Act §5.